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Polyacrylamide nanoparticles bearing two orthogonal reactive functionalities were prepared by reverse
microemulsion polymerisation. Water-soluble photosensitisers and peptide or carbohydrate moieties
were sequentially attached to the new nanospecies by orthogonal conjugations based on copper-
catalysed azide-alkyne cycloaddition and isothiocyanate chemistry.
Introduction
Growing interest in the application of nanotechnology in
biomedical research has encouraged great efforts in devising
improved materials for the generation of multifunctional nano-
devices designed for targeted drug delivery, diagnostic imaging
and biosensing. Thanks to favourable physicochemical proper-
ties, cross-linked polyacrylamide has gained popularity as
a support for biocompatible nanomaterials.1–9 Polyacrylamide
nanoparticles (PANPs) are hydrophilic and give stable colloidal
dispersions in water, hence they are suitable for biologic appli-
cations. An appealing feature of polyacrylamide nanoparticles is
their versatility, resulting from their chemical flexibility. Careful
choice of polymerisation conditions, for example, allows control
over the size of the resulting nanospecies,10,11 a parameter that
dictates the behaviour of the nanoparticle in living systems, by
affecting its cell penetration ability, intracellular localisation, and
pharmacokinetic profile (i.e.: plasma half-life, distribution and
clearance).12–14 Cargoes can be loaded on polyacrylamide nano-
particles either by encapsulation within the polymer network or
by conjugation to reactive functionalities, which can be engi-
neered on the surface of the particle by including suitably func-
tionalised acrylamides in the polymerisation step.15 Thus,
polyacrylamide nanoparticles have been decorated with a wide
variety of molecules, including targeting agents (e.g.: peptides,
carbohydrates, aptamers, oligonucleotides, lipids, etc.),15,16
fluorescent dyes, reporter molecules,17 drugs, or contrast
agents.18,19
The field of photodynamic therapy and photodiagnosis greatly
benefitted from the advent of nanotechnology.20–23 The associa-
tion of photosensitisers with polyacrylamide nanoparticles
opened the way to the generation of light responsive nano-
devices, which have applications as therapeutic, diagnostic and
investigative tools. The incorporation of a photosensitiser into
a nanoparticle is an effective way to overcome the poor water
solubility displayed by many photosensitisers, to achieve higher
loading of photosensitiser in the target cells, and in many
instances to prolong the half-life of the photosensitiser in plasma,
in particular when the surface of the nanoconjugate is coated
with polyethylene glycol (PEG) to delay opsonisation.24,25
Luminescent probes and polyacrylamide nanoparticles can
also be associated to generate nanosensors for monitoring bio-
logical processes in living systems.26–30 Due to their size, nano-
sensors allow measurements to be performed within a single cell,
with minimal perturbation of the system. In nanosensors, the
polymer constituting the core of the particle entraps a fluorescent
dye that responds to the variations of the concentration of
a given analyte in the intracellular environment by modifying its
fluorescence emission profile. Thus, changes in the fluorescence
signal following the application of an external stimulus provide
real time information on the fluctuations of the level of the
analyte, and on the biological processes associated with such
fluctuations. The use of nanosensors presents several advantages
over the use of stand-alone fluorescent dyes: the choice of
the fluorescent probe can be solely based on its sensitivity to the
analyte of interest and on its emission profile, because the
hydrophilic matrix circumvents all issues related to low water
solubility, instability and toxicity of the dye. Once incorporated
in the polyacrylamide matrix, even hydrophobic dyes can be used
in aqueous solutions, and because interactions of the encapsu-
lated probe with macromolecules are prevented, its degradation
by enzymes and its association with proteins or membranes are
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reduced. For the same reason, the cell is protected from toxic
effect exerted by the dye.
Several examples of nanosensors comprising a nanoparticle
and a porphyrinic photosensitiser have been described.31–39 The
majority of such sensors were conceived for the measurement of
oxygen concentration inside living cells: platinum complexes of
porphyrins, whose phosphorescent lifetime is inversely propor-
tional to the pO2 in the surrounding microenvironment, are the
sensing components of such nanodevices.32–38
In the course of our studies concerning the role of reactive
oxygen species in cell signalling, we became interested in studying
the mobilization of intracellular calcium following singlet oxygen
production. We previously reported the synthesis of a nano-
sensor comprising of a calcium-sensitive fluorophore (calcium
green 1, CG-1) embedded in a porphyrin-conjugated poly-
acrylamide nanoparticle (Fig. 1, A), as a self-standing nano-
device able to elicit a controlled perturbation of the cellular
system (production of singlet oxygen) and to register the down-
stream events of the cellular response to such variation (calcium
ion mobilization).31
With the aim of improving cellular delivery of the nano-
sensors, we reasoned that a cell penetration enhancing moiety or
a targeting agent could be conjugated to the surface of the
nanodevice alongside the porphyrin, provided a second reactive
functionality could be introduced on the polymer. (Fig. 1, B). In
order to maintain control over the selectivity of the conjugations,
the two reactive functionalities displayed on the new nano-
particles would need to display no overlapping reactivity, so that
either one of them could be selectively conjugated to a given
cargo.
The functionalisation of polyacrylamide nanoparticles
with amino groups is widely documented.8,17,18,31,40,41 To
generate these species, a suitable acrylamide containing an
amino-group is copolymerised with acrylamide and N,N-meth-
ylenebisacrylamide as the cross-linker, under reverse-phase
microemulsion polymerisation conditions. The relative amount
of cross-linker used during the polymerisation can be varied to
fine tune the structure of the nanogel and the properties of the
nanospecies generated (pore size, elasticity, swelling, etc.).40–42
Numerous examples of efficient decoration of amino-func-
tionalised polyacrylamide nanoparticles with cargoes of diverse
nature are reported in the literature.8,17,18,31,43,44
We have previously shown that porphyrins bearing an iso-
thiocyanate group or a hydroxysuccinimide-activated carboxylic
function can be attached to the surface of amino-functionalised
polyacrylamide nanoparticles.4,31 The synthesis of nanoparticles
bearing alkyne or azide groups, reactive under CuAAC condi-
tions, was also reported:45–47 in particular, we have shown that
alkyne-functionalised polyacrylamide nanoparticles successfully
undergo conjugation with TAMRA derivative and peptido-
coumarins in the presence of tetrakis(acetonitrile) copper(I)
hexafluorophosphate and TBTA.48 In these reports, the intro-
duction of the functional groups on the particle surface was
achieved via a common strategy, i.e. by adding the functionalised
acrylamide to the polymerisation mixture. On the basis of these
studies, we envisaged that the combined use of amino- and azido-
(or alkyne)-bearing acrylamides during the polymerisation step
would afford nanospecies displaying the two required orthog-
onal functionalities which, under the appropriate conditions,
could selectively take part in conjugation with different cargoes.
Several examples of polymers prepared under controlled
polymerisation conditions (living free-radical polymerisation)
and displaying orthogonal functionalities have been reported in
the literature,49–55 but to the best of our knowledge it has never
been exploited for the assembly of multifunctional poly-
acrylamide nanospecies under reverse phase microemulsion
polymerisation.
Results and discussion
While N-(3-aminopropyl)methacrylamide hydrochloride is
a commercially available compound, no acrylamide functional-
ised with an azide or a triple bond can be purchased. Therefore
we first focused on the synthesis of two acrylamide monomers
with comparable chain lengths, bearing the desired groups.
Amino-azide 1 in its Boc-protected form was obtained starting
from 2-(2-aminoethoxy)ethanol in two steps on a multi-gram
scale.56 Boc-protected amino-alkyne 2 was also obtained in two
steps from ethanolamine. The desired acrylamides 3 and 4 were
prepared in moderate yields by reaction of 1 and 2 with acryloyl
chloride following HCl-mediated Boc-deprotection. (Scheme 1).
Acrylamides 3 and 4 were efficiently incorporated into poly-
acrylamide nanoparticles under reverse-phase microemulsion
polymerisation conditions.27,48 (Scheme 2, Box 1) The desired
nanospecies 5 and 6 were obtained in 81 and 88% yield, respec-
tively. IR spectra of the particles obtained showed a band at 2111
Fig. 1 Scheme 1































































cm!1 for 5, which is diagnostic for the stretching of N–N bond in
the azido groups, and a very weak band at 2090 cm!1 for 6,
generated by the stretching of the triple bonds.
A further confirmation of the presence of the desired reactive
functionalities on the nanoparticles was provided by the
successful conjugation of 5 and 6 with ‘‘clickable’’ porphyrins 7
and 8, respectively, under Cu(I)-catalysed triazole formation
conditions.57 Alkyne-bearing porphyrin 7 and azide-bearing
porphyrin 8 were obtained by coupling hydroxysuccinimido-
ester 9 with amines 10 and 11 in NaHCO3 buffer. (Scheme 3) The
choice of using 7 and 8 as zinc complexes was made in order to
prevent the sequestration of copper ions by the macrocycle
during CuAAC. The conjugation reaction occurred smoothly in
water at room temperature, in the presence of CuSO4 and sodium
ascorbate. (Scheme 2, Box 2) Gel filtration on Sephadex G25
provided an expeditious mean to separate the nanoconjugates
from the catalysts and non-reacted porphyrin.58 Nanoconjugates
12 and 13 were recovered in 95 and 83% yields, respectively,
following precipitation with ethanol and filtration.
Having verified the usefulness of acrylamides 3 and 4 for the
introduction of azides and terminal alkynes on polyacrylamide
nanoparticles, we turned our attention to the preparation of
doubly-functionalised species. To this end, we modified the
protocol by replacing the 1% of functionalised acrylamide in the
mixture of monomers with 0.5% of N-(3-aminopropyl)meth-
acrylamide hydrochloride (APMA) and 0.5% of either 3 or 4. We
were pleased to observe that in both cases the polymerisation
afforded bifunctionalised nanospecies 14 and 15 (Scheme 2),
whose average hydrodynamic diameter did not differ signifi-
cantly from the diameter exhibited by the monofunctionalised
Scheme 2
Scheme 3































































particles. (Table 1). The presence of the alkyne and azide func-
tionalities was again verified by IR, while the presence of the
amino group was revealed by means of fluorescamine staining.59
With the aim of assessing the versatility of the new bifunc-
tionalised polyacrylamide nanospecies, and to verify the feasi-
bility of orthogonal sequential double-conjugations, we selected
a group of conjugatable molecules to decorate the particles.
(Scheme 4) Bearing in mind that this work originated from the
need of associating nanoparticles with both photosensitisers and
cell-penetration or cell-targeting entities, we selected a small
group of molecules representative of both groups. Porphyrins 7,
8, and 16,60 and phthalocyanine 17 were chosen as examples of
photosensitisers, whereas RGD-containing cyclo-pentapeptides
18 and 19 and 1-propargyloxymannose 20 as models for target-
ing moieties. Although RGD-containing peptides8,46,61–65 and
mannose66–69 have already been used in association with a variety
of nanoparticles to improve their receptor-mediated targeting
and cellular uptake, in this work they were selected as models to
study the feasibility of the conjugation of peptides and carbo-
hydrates to the new doubly-functionalised nanospecies. As
shown in Scheme 3, all the molecules selected were engineered to
display groups which would provide them with reactivity
towards amines, azides, or triple bonds. With ‘‘clickable’’
porphyrins 7 and 8 already in our hands, we chose iso-
thiocyanato porphyrin 16 as an amino-reactive photosensitiser.
Porphyrin 16was prepared in quantitative yield by metallation of
the corresponding free base in 10 mMNaHCO3 buffer. Although
the conjugation of 16 to amino-functionalised nanoparticles does
not require the presence of metal ions in the reaction mixture, the
use of a zinc-porphyrin was necessary because the resulting
nanoconjugate would be exposed to copper ions under the
CuAAC conditions of the second ligation step. RGD-containing
cyclopentapeptides were synthesised by Fmoc-SPPS, according
to literature procedures.70 The azide group was incorporated in
peptide 18 by coupling Fmoc-3-azidolysine71 during chain elon-
gation, whereas the isothiocyanate function of 19 was installed
on the side chain of Lys by treatment of the corresponding
amino-derivative with 1,10-thiocarbonyldi-2(1H)pyridone.72
Because amino-functionalised polyacrylamide nanoparticles
have been reported to be prone to irreversible aggregation,48
a behaviour that has been ascribed to the Michael addition of the
amino-groups onto residual acrylamide moieties on the surface
of the particle, we envisaged that the attachment of the amino-
reactive cargo should be carried out before the CuAAC conju-
gation. (Scheme 2, Box 3).
Thus, nanoparticles 15 were first treated with isothiocyanate
porphyrin 16 in the presence of 30 mM triethylamine. The
resulting porphyrin-conjugated particles 21 were then exposed to
azide-functionalised cyclopentapeptide 18 under the conditions
described above. The doubly-decorated nanospecies 22 were
obtained in 75% yield over two steps. Exchanging the reactive
functionalities on the cargo molecules did not hamper the double
conjugation, as we confirmed by exposing particles 15 first to
cyclopentapeptide isothiocyanate 19 to afford conjugate 23, and
then to porphyrin 8 to give nanospecies 24. The final nano-
conjugate was obtained in 63% overall yield. (Scheme 4) A
similar conjugate was obtained starting from particles 14, which
reacted with cyclopentapeptide 19 in the presence of triethyl-
amine, yielding 25, and subsequently with porphyrin 7 under
CuAAC conditions to give conjugate 26, confirming that the
reactivity of the azide group is maintained on the bifunctional-
ised nanoparticles. (Fig. 2) Treatment of nanospecies 27,
obtained by reaction of porphyrin 16 on particles 14, with 1-
propargyloxymannose 2012 under CuAAC conditions yielded
conjugate 28 in 90% yield. Treatment of nanoconjugate 23 with
azido-phthalocyanine 1773 in 10% aqueous DMSO in CuAAC
conditions, gave nanoparticles 29 in 91% yield. Fig. 2 summarises
the nanoconjugates obtained by applying the protocols devised
with bifunctionalised nanoparticles and different permutations
of the conjugatable molecules we selected.
Characterisation of the nanoconjugates
The hydrodynamic size of the nanoconjugates was measured by
photon correlation spectroscopy. (Table 1 and Table 2). The
conjugated nanospecies showed a marked increase in hydrody-
namic radius compared to the native particles. These observa-
tions are in agreement with our previous findings,4 and can be
explained on the basis of the increased thickness of the counter-
ions corona tightly associated with the nanoparticle, caused by
the covalent ligation of tri-cationic molecules on the surface of
the gel.74,75 The presence of positive charges could also cause the
swelling of particles because of the increased osmotic pressure in
the proximity of the nanogel.76 The efficiency of the attachment
of the photosensitisers to the particles was evaluated by UV-
visible spectroscopy. The UV-visible spectra of particles 22 and
particles 29 show the typical profiles of metal complexes of
porphyrins and phthalocyanines. (Fig. 3) To reveal the presence
of mannose on particles 28 we relied on a colorimetric test based
on the reaction of carbohydrates with phenol in the presence of
concentrated sulfuric acid, described by Masuko et al.77 The
presence of mannose is evidenced by the development of a broad
band centred at 470–480 nm in the absorption spectrum. (Fig. 4)
A similar assay has been previously used to estimate the loading
of mannose on mesoporous silica nanoparticles.68 The presence
of peptides 18 and 19 on nanoparticles was detected with the
Sakaguchi test,78 which reveals the presence of guanidine on the
side-chain of Arg. (Fig. 5) An application of this assay to detect
the presence of RGD-containing peptides anchored on a solid
support has been reported previously.79 The tests described
above were intended to be qualitative assays, aimed at verifying
the effectiveness of the conjugation reactions. The results
obtained confirmed that the presence of the first cargo on the
particle does not prevent the attachment of the second one,
indicating that the reactivity of the two groups is maintained
throughout the whole conjugation process.
Following our original concept of obtaining doubly-conju-
gated Ca-sensing nanoparticles, we prepared nanoparticles 30,
displaying alkyne and amine groups and entrapping
Table 1





































































dextran-supported CG-1.31 (Scheme 5) The two conjugation
steps required for the preparation of nanoconjugates 31 were
performed sequentially, without isolating the intermediate
conjugate. (Scheme 5) To this end, particles 30 were first treated
with porphyrin 16 in the presence of triethylamine, and then
peptide 18, CuSO4 and sodium ascorbate were added to the
aqueous solution of the conjugated nanospecies, after gel filtra-
tion. The presence of both cargoes was verified as described
above. The sensors show a linear response to the increasing
calcium concentration over the range of 0–12 nM (y " 0.942x +
134.85, R2 " 0.9799). These results are in agreement with data
previously generated, confirming that embedding CG-1 within
porphyrin-coated polyacrylamide nanoparticles does not impair
its sensitivity to calcium ions in the surrounding environment.31
Conclusions
This work shows that the insertion of two orthogonal function-
alities on polyacrylamide nanoparticles can be achieved, and that
the reactivity of such groups can be successfully exploited to
sequentially load the particles with two different cargoes. To the
best of our knowledge this represents the first example of the
application of orthogonal conjugation on polyacrylamide
nanoparticles. The insertion of the two reactive groups on the
particle is achieved via standard reverse phase microemulsion
polymerisation techniques, yet it gives access to nanodevices with
a high degree of functionalisation and complexity. The mild
reaction protocols and expeditious purification make this novel




Particles Yield (%) Zave (nm) Particles Yield (%) Zave (nm)
12 95 102.3 25 74 103.1
13 83 92.3 26 97 92.7
21 82 99.8 27 79 110.1
22 92 96.9 28 90 98.4
23 70 89.5 29 91 69.2
24 90 70.0 31 88 71.7































































to nanoparticles; however we anticipate that this method will
have a broad relevance, because it will be applicable to conjugate




1H and 13C NMR spectra were recorded on JEOL Eclipse 400
and JEOL Lambda 400 spectrometers (operating at 400 MHz
for 1H and 100 MHz for 13C). CDCl3, DMSO-d6, and MeOH-d3
were used as solvents. Chemical shifts (d) are reported in parts
per million (ppm), referenced to either CHCl3 (
1H, 7.26 ppm;
13C, 77.16 ppm) or DMSO (1H, 2.50 ppm; 13C, 39.52 ppm) or
MeOH (1H, 3.31 ppm; 13C, 49.00 ppm). Coupling constants (J)
are recorded in Hz and significant multiplicities described by
singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br),
multiplet (m), or doublet of doublets (dd). A Malvern Photon
Correlation Spectrometer equipped with a 70 mW blue laser
operating at 470 nm at an angle of 90# was used for the PCS
measurements. The measurements were performed at room
temperature, at a concentration of 5 mg mL!1 of nanospecies in
7 mM aqueous NaCl, unless otherwise stated, and the solutions
were filtered through a 0.22 mm filter (Millex GP) previous to
the measurements. CI, EI, and pAPCI mass spectra were per-
formed at the EPSRC Mass Spectrometry Service (Swansea).
ESI mass spectra were performed on a Varian 500-MS ion trap
spectrometer, equipped with a Varian Prostar 212LC binary
gradient pumping system and a Varian ProStar 410 autosam-
pler. A standard Varian ESI source was used operating in +ve
ion mode. Data was acquired and processed using Varian
Workstation software. MALDI mass spectra were performed
on a Bruker Reflex IV MALDI-TOF, operated in reflectron
mode and monitoring positive ions. Data is acquired and pro-
cessed using Bruker Compass software. 1,8-Dihydroxy-9,10-
dihydroanthracen-9-one (dithranol) was used as the matrix.
UV–visible spectra were recorded on a Varian Cary spectro-
photometer. Fluorescence spectra were recorded on a Cary
Eclipse Fluorimeter. Flash chromatography was carried out on
silica gel 60 (MP Biomedicals, 32 !63 mm). Analytical TLC was
carried out on aluminium sheets pre-coated with silica gel
60 (Fluka, 0.2 mm thick). Commercial solvents and reagents
were used without further purification unless stated otherwise.
Porphyrins 5-(4-isothiocyanatophenyl)-10,15,20-tris-[(4-meth-
ylpyridynium)yl]porphyrin trichloride and 5-[4-(succinimide-
N-oxycarbonyl)phenyl]-10,15,20-tris-[(4-methylpyridynium)yl]
porphyrin trichloride were prepared according to literature
procedures.60
Chemical reagents were purchased from Sigma-Aldrich,
Fluka, Acros, Lancaster, Alfa Aesar, TCI Europe, and Nova-
biochem at the highest grade of purity available, and were used
as received, unless otherwise stated. Dichloromethane and THF
were dried by filtration through alumina and storage over
Fig. 3
Fig. 4 Absorption spectra obtained after Sakaguchi test.
Fig. 5 Absorption spectra obtained after Masuko test.
Scheme 5































































activated molecular sieves.80 All other solvents were purchased
from Fisher Scientific and used as received. Deionised water
was obtained from a Millipore Milli-Q system. Gel filtrations
were performed on Sephadex! G-25 medium, using pre-packed
PD-10 columns (GE Healthcare, UK), using deionised water as
the eluent. Filtrations through membranes were performed on
Sartolon! polyamide filters, 25 mm, 0.20 mm pores. Solid phase
extractions were performed on Supelco Discovery DSC-18
cartridges (1 g). RP-HPLC analyses were performed on
a system consisting of a Perkin Elmer series 200 LC pump,
and a Perkin Elmer 785A UV/vis detector. The separations
were performed on a Gemini C18, 5 m, 150 $ 4.6 mm, 110 !A
(Phenomenex, UK), equipped with a SecurityGuard C18 (ODS)
4 $ 3.0 mm ID guard column (Phenomenex, UK) at a flow rate
of 1 mL min!1. The mobile phase consisted of 0.1% TFA in
water (solvent A) and 0.1% TFA in acetonitrile (solvent B).
Gradient: 0.0–10.0 min 0–95% solvent B, 10.0–15.0 min 95%
solvent B, 15.0–15.1 min at 95–5% solvent B, 15.1–18.0 min 5%
solvent B.
General procedure for the synthesis of functionalised
acrylamides: 2-(2-azidoethoxy)ethyl acrylamide 3
2-(2-azidoethoxy)-N-t-butoxycarbonylethylamine (460 mg, 2
mmol) was treated with 4 MHCl in 1,4-dioxane (1 mL, 4 mmol).
The resulting solution was stirred at room temperature for 1 h,
and the solvent was evaporated. The residue was triturated with
diethyl ether and thoroughly dried in vacuo. The solid residue
was taken in dry DCM and the resulting solution was maintained
in an Ar atmosphere and cooled at 0 #C. Triethylamine (613 mL,
4.4 mmol) was added to the solution, followed by dropwise
addition of acryloyl chloride (194 mL, 2.4 mmol). The mixture
was stirred for 4 h, while being allowed to reach room temper-
ature, then it was diluted with DCM, and washed with 0.1 M
aqueous HCl, and with brine. The organic layer was dried
(MgSO4) and the solvent was evaporated. The desired compound
was isolated by column chromatography (DCM/Et2O " 1/1),
yielding a pale yellow liquid (168 mg, 50%). 1H NMR: (CDCl3) d:
6.30 (1H, dd, Jtrans 16.9, Jgem 2.7, CHHCHCONHR), 6.11 (1H,
dd, Jtrans 16.9, Jcis 10.3, CH2CHCONHR), 6.00 (1H, bs, NH),
5.65 (1H, dd, Jcis 10.3, Jgem 2.7, CHHCHCONHR), 3.69 (2H, t, J
4.4, CONHCH2CH2OR), 3.62–3.55 (4H, m, CON-
HCH2CH2OCH2R), 3.38 (2H, t, J 3.8, ROCH2CH2N3);
13C
NMR: (CDCl3) d: 165.5, 130.7, 126.5, 70.2, 67.8, 50.6, 39.1
pAPCI-MS (m/z): calcd. for C7H13N4O2: 185.1033; found:
185.1029 [M + H]+.
2-(prop-2-ynyloxy)ethyl acrylamide 4
Scale: 2 mmol, yield 34%, 52.3 mg, pale yellow fluid.
1H NMR: (CDCl3) d: 6.29 (1H, dd, Jtrans 12.9, Jgem 1.2,
CHHCHCONHR), 6.11 (1H, dd, Jtrans 12.9, Jcis 7.7,
CH2CHCONHR), 6.0 (1H, bs, NH), 5.65 (1H, dd, Jcis 7.7, Jgem
1.2, CHHCHCONHR), 4.19 (2H, s, ROCH2CCH), 3.65 (2H, t, J
3.5, NHCH2CH2O), 3.58 (2H, t, J 3.5, NHCH2CH2O), 2.47 (1H,
s, CCH); 13C NMR: (CDCl3) d: 165.5, 130.7, 126.5, 79.3, 74.8,
68.6, 58.3, 39.1 CI-MS (m/z): calcd. for C7H12NO2: 154.0863;
found: 154.0863 [M + H]+.
General procedure for the synthesis of functionalised water




0.2 mmol) was treated with 4 M HCl in 1,4-dioxane (0.5 mL,
2.0 mmol). The resulting solution was stirred at room tempera-
ture for 1 h, and the solvent was evaporated. The residue was
triturated with diethyl ether and thoroughly dried in vacuo. To
the residue, porphyrin NHS (77 mg, 0.08 mmol) was added,
followed by 0.1% (w/v) aqueous NaHCO3 (5 mL). The resulting
mixture was stirred for 1 h, at room temperature, poured in 10%
aqueous NH4PF6 (25 mL), and the precipitate formed was
collected by filtration through paper. The solid was dissolved in
acetone (30 mL) and the precipitation of desired compound was
promoted by addition of a 20% solution of TBAC in acetone (3
mL). The solid was collected by filtration and was crystallised
from methanol/diethyl ether. (Dark purple solid, 37 mg, 49%).
HPLC: tR: 6.00 min.
1H NMR: (DMSO-d6) d: 9.57–9.57 (6H, 10 + 15 + 20-m-Ar),
9.17 (6H, br, b-H), 9.07–9.00 (m, 8H, b-H and 10 + 15 + 20-o-
Ar), 8.40 (2H, d, J 7.7, 5-o-Ar), 8.32 (2H, d, J 7.7, 5-m-Ar), 4.78–
4.76 (9H, m, s, CH3), 4.27 (2H, br, OCH2CCH), 3.75–3.72 (2H,
m, NHCH2CH2O), 3.63–3.62 (2H, m, NHCH2CH2O), 3.55–3.54
(1H, m, OCH2CCH);
13C NMR: (DMSO-d6) d: 166.0, 156.4,
144.2, 143.0, 134.1, 132.0, 126.1, 121.8, 115.4, 114.8, 80.4, 77.3,
67.8, 57.4, 47.8; MALDI-MS (m/z): calcd. for C50H45N8O2:
789.3649, found: 789.3634 [M-3Cl + 2H]+. UV/vis: (H2O) l (%):
421 (100), 518 (6.4), 556 (2.8), 583 (3.5), 639 (1.9); log 3421: 5.31.
5-{4-[2-(2-azidoethoxy)ethyl]phenyl}-10,15,20-tris-[(4-
methylpyridynium)yl]porphyrin trichloride 8
Scale: 0.1 mmol, 52 mg, 56%, dark purple solid. 1H NMR:
(DMSO-d6) d: 9.55–9.52 (6H, 10 + 15 + 20-m-Ar), 9.16 (br, 4H,
b-H), 9.07–9.00 (m, 10H, b-H and 10 + 15 + 20-o-Ar), 8.38 (2H,
d, J 9.2), 8.32 (2H, d, J 9.2), 4.75–4.74 (9H, m, s, CH3), 3.75–3.73
(4H, m, CONHCH2CH2OCH2R), 3.65–3.62 (2H, m, CON-
HCH2CH2OCH2R), 3.49 (2H, t, J 4.7, ROCH2CH2N3), -3.02
(2H, s, pyrrole NH); 13CNMR: (DMSO-d6) d: 166.1, 156.5, 156.4,
144.2, 143.0, 134.2, 134.1, 132.1, 126.1, 121.9, 115.4, 114.7, 69.0,
68.8, 50.1, 47.8; MALDI-MS (m/z): calcd. for C49H45N11O2:
819.3741, found: 819.4056 [M- 3Cl + H]+; UV/vis: (H2O) l (%):
423 (100), 519 (6.4), 560 (3.0), 585 (3.5), 640 (2.0); log 3423: 5.34.
General procedure for the complexation of cationic porphyrins:
5-(4-isothiocyanatophenyl)-10,15,20-tris-[(4-methylpyridynium)
yl]porphyrinato zinc(II) trichloride
An aqueous solution (10 mL) of 16 (63 mg, 0.07 mmol), was
treated with ZnOAc2 (20 mg, 0.1 mmol), and the resulting
mixture was stirred at room temperature for 10 min. A 10% (w/v)
aqueous solution of NH4PF6 (10 mL) was added to the reaction
mixture and the resulting suspension was centrifugated. The
precipitate was dissolved in acetone (10 mL) and the precipita-
tion of the desired porphyrin was promoted by addition of a 20%
solution of TBAC in acetone (1 mL). The solid was recovered by
filtration and crystallised from methanol/diethyl ether. (Green
solid, 56 mg, 90%). HPLC: tR: 6.50 min;
1H NMR: (DMSO-d6) d:































































9.33–9.31 (6H, 10 + 15 + 20-m-Ar), 9.13–9.11 (4H, m, b-H), 9.03–
8.99 (4H, b-H), 8.91–8.89 (6H, 10 + 15 + 20-o-Ar), 8.54 (2H, d, J
8.3, 5-o-Ar), 8.40 (2H, d, J 8.3, 5-m-Ar), 4.8 (9H, s, CH3);
13C
NMR: (DMSO-d6) d: 172.2, 161.3, 151.8, 150.3, 150.2, 149.9,
144.8, 136.2, 134.7, 134.1, 133.6, 133.3, 132.8, 129.7, 116.8;
MALDI-MS (m/z): calcd. for C45H33N8SZn: 781.1824, found:
781.2476 [M- 3Cl + H]+; UV/vis: (H2O) l (%): 435 (100), 565
(8.6), 607 (5.5); log 3435: 5.09.
5-{4-[2-(2-azidoethoxy)ethyl]phenyl}-10,15,20-tris-[(4-
methylpyridynium)yl]porphyrinato zinc(II) trichloride
Green solid. Scale: 0.65 mmol, yield 91%, 58 mg. HPLC: tR: 6.15
min; 1H NMR: (MeOH-d3) d: 9.35–9.31 (6H, m, 10 + 15 + 20-m-
Ar), 9.12 (4H, s, b-H), 9.01–8.97 (4H, s, b-H), 8.92–8.88 (6H, m,
10 + 15 + 20-o-Ar), 8.27–8.21 (4H, m, 5-o-Ar and 5-m-Ar), 4.79
(9H, s, CH3), 3.78–3.72 (6H, m, CONHCH2CH2OCH2CH2N3),
3.42 (2H, t, J 4.9, ROCH2CH2N3);
13C NMR: (MeOH-d3) d:
167.3, 158.5, 149.3, 147.4, 147.3, 146.9, 143.9, 142.0, 141.9, 132.7,
131.8, 131.2, 130.6, 130.4, 129.6, 123.9, 121.5, 113.9, 113.1, 68.1,
67.6, 49.1, 38.2; MALDI-MS (m/z): calcd. for C49H42N11O2Zn:
880.2800, found: 880.3026 [M- 3Cl]+. UV/vis: (H2O) l (%): 434
(100), 564 (7.2), 606 (3.2); log 3434: 5.26.
5-{4-[2-(2-propynyloxy)ethyl]phenyl}-10,15,20-tris-[(4-
methylpyridynium)yl]porphyrinato zinc(II) trichloride
Green solid. Scale: 0.45 mmol, yield 93%, 39 mg. HPLC: tR: 5.98
min; 1H NMR: (MeOH-d3) d: 9.35–9.32 (6H, m, 10 + 15 + 20-o-
Ar), 9.31–9.10 (4H, s, b-H), 8.98 (4H, s, b-H), 8.91–8.89 (6H, m,
10 + 15 + 20-m-Ar), 8.30–8.23 (4H, m, 5-o-Ar and 5-m-Ar), 4.29
(2H, d, J 2.9, OCH2CCH), 3.84 (2H, t, J 5.5, NHCH2CH2O),
3.75 (2H, t, J 5.5, NHCH2CH2O), 2.92 (1H, t, J 2.9, OCH2CCH);
13C NMR: (MeOH-d3) d: 169.7, 160.7, 151.6, 151.5, 149.6, 149.5,
149.2, 146.3, 144.2, 134.7, 133.4, 133.4, 132.8, 132.6, 131.9, 128.1,
126.1, 116.1, 115.3, 80.0, 75.4, 68.7, 58.3, 57.7, 40.3; MALDI-MS
(m/z): calcd. for C50H41N8O2Zn: 849.2627, found: 849.2728 [M-
3Cl]+; UV/vis: (H2O) l (%): 434 (100), 564 (9.8), 608 (6.6);
log 3434: 5.27.
General procedure for solid-phase peptide synthesis. H-D(tBu)fK
(3-N3)R(Pmc)G-OH
The synthesis of the protected cyclopentapeptides was accom-
plished according to the Fmoc/t-Bu strategy manually in a 6 mL
fritted SPE tube (Supelco, UK), equipped with a cap and plastic
valve (Chromabond, UK). Loading of the resin was achieved by
treating 2-chlorotrityl chloride polystyrene resin (1 g, 1.4 mmol)
with a solution of N-a-Fmoc-glycine (832 mg, 2.8 mmol) and
DIPEA (1950 mL, 11.2 mmol) in dry DCM (10 mL) for 60 min.
Unreacted sites on the resin were capped by treatment with
a solution of DCM/MeOH/DIPEA (3 : 1 : 0.5 v/v/v, 2$ 15 min).
The first residue loading was measured spectrophotometrically,
and was estimated to be 1.37 mmol g!1. Coupling reactions were
performed by treating the resin (400 mg) with a solution of
Fmoc-amino acid (2 equiv relative to the resin loading), PyBOP
(1.9 equiv) and diisopropylethylamine (4 equiv) in DMF (10 mL
g!1 resin) for 60 min. The efficiency of the coupling reactions was
assessed by Kaiser test.81 N-Fmoc deprotection was performed
by treatment piperidine/DMF (1 : 4 v/v, 10 mL g!1 resin, 4 $ 3
min). The cleavage was performed by treating the resin with
TFA/MeOH (1 : 99 v/v, 10$ 2 min). The cleavage solutions were
neutralised by addition to pyridine/MeOH (1 : 9 v/v, 20 mL),
concentrated to small volume and precipitated from ice-cold
water. The precipitate was washed again with ice cold water
(20 mL) and dried in vacuo. The residue was dissolved in the
minimum of methylene chloride and precipitated from diethyl
ether. The white solid was triturated diethyl ether to obtain the
crude peptide that was used in the next step without further
purification. The cleavage performed onto 500 mg of peptidyl
resin afforded 150 mg of crude peptide (40% based on loading of
first residue). RP-HPLC (detector: l " 220 nm): tR " 9.87 min;
ESI-MS (m/z): calcd. for C45H68N11O11S: 970.4815; found:
970.4712 [M + H]+.
Peptide H-D(tBu)fK(Boc)R(Pmc)G-OH
Cleavage performed onto 500 mg of peptidyl resin afforded
220 mg (0.19 mmol) of crude peptide as a white solid (54% based
on loading of the first residue). RP-HPLC (detector: l "
220 nm): tR " 10.07 min; ESI-MS (m/z): calcd. for
C50H78N9O13S: 1044.5362, found: 1044.5086 [M + H]
+.
General procedure for cyclization reactions. Peptide cyclo[D
(tBu)fK(3-N3)R(Pmc)G]
A 0.5 mM solution of linear protected peptide 18, whose pH
value was adjusted to 8–9 by addition of DIPEA, was treated
with PyBOP (1 equiv). The solution was stirred at room
temperature for 1 h. Solvent was removed under reduced pres-
sure and the residue dissolved in the minimum of methylene
chloride. Diethyl ether was added to precipitate crude peptide,
which was triturated and washed with diethyl ether (3 $ 10 mL),
and in the next step without further purification. RP-HPLC (l "
220 nm): tR " 11.57 min; ESI-MS (m/z): calcd. for
C45H65N11O10S: 951.4637; found: 951.4592 [M + H]
+.
Peptide cyclo[D(tBu)fK(Boc)R(Pmc)G]
White solid, RP-HPLC (detector: l " 220 nm): tR " 11.47 min;
ESI-MS (m/z): calcd. for C50H75N9O12S: 1025.5256; found:
1025.5140 [M + H]+.
General procedure for the deprotection of the peptides. Peptide
cyclo[DfK(3-N3)RG]
Protected peptide 18 (72 mg) was treated with TFA/TIS/water
(95/2.5/2.5, 1 mL) at room temperature for 2 h. The solvent were
evaporated in reduced pressure and the residue was taken in
a TFA (0.2 mL) and precipitated with diethyl ether (10 mL).
Washing with diethyl ether was repeated 3 times, and the crude
peptide was purified by Supelco Discovery DSC-18 cartridges
(1 g), eluting with 0.1% TFA in acetonitrile/water (5/95). The
solvent was evaporated and the residue was taken in MeOH. The
solid residue was filtered off, and the TFA salt of the peptide was
precipitated from the solution by addition of diethyl ether,
yielding a white solid (58 mg, 82%) RP-HPLC (detector: l " 220
nm): tR " 6.33 min; ESI-MS: (C27H41N9O7 requires 603.3129).
































































The deprotection was performed onto 80 mg of protected
cyclopeptide. White solid (68 mg, 86%). RP-HPLC (detector: l"
220 nm): tR " 5.80 min; ESI-MS (m/z): calcd. for C27H41N9O7:
603.3129; found: 603.3093 [M + H]+.
Synthesis of cyclopeptide 19
To a solution of cyclo[DfKRG] (30 mg) in 20 mL of DMF/DCM
(1/1 v/v), 1,10-thiocarbonyldi-2(1H)piridone (8 mg, 0.04 mmol)
was added, and the solution was stirred at room temperature for
3 h. DCM was evaporated in vacuo, and the resulting solution
was added to diethyl ether (50 mL). The precipitate was collected
by centrifugation and triturated with diethyl ether, to afford the
desired peptide which was used for the conjugation reactions
without further purification. White solid (25 mg, 77%). RP-
HPLC (detector: l " 220 nm): tR " 7.38 min; ESI-MS (m/z):
calcd. for C28H39N9O7S: 645.2693; found: 645.2720 [M + H]
+.
General procedure for the synthesis of functionalised
polyacrylamide nanoparticles: alkyne-functionalised
nanoparticles 6
Degassed hexane (42 mL) was added to a stirred solution of Brij!
30 (3.08 g, 8.5 mmol) and dioctyl sulfosuccinate sodium salt
(1.59 g, 3.6 mmol). The mixture was allowed to stir under argon
until complete dissolution of the surfactants. A solution of
acrylamide (527 mg, 7.6 mmol), 4 (13 mg, 0.08 mmol), and N,N0-
methylenebisacrylamide (160 mg, 1.0 mmol) in water (1.8 mL)
was added to the hexane mixture. 10% aqueous ice-cold ammo-
nium persulfate (30 mL) was added to the reaction vessel, fol-
lowed by N,N,N0,N0-tetramethylethylenediamine (15 mL), and
the reaction mixture allowed to stir at room temperature under
argon for two hours. Excess hexane was evaporated in vacuo, and
the resulting white viscous liquid was washed with ethanol and
centrifuged (7$ 50 ml, 10 min, 4000 rpm). The solid was taken in
ethanol and isolated by filtration through membrane, and dried
in vacuo to yield the desired alkyne functionalized nanospecies as
a white solid (621 mg, 88%). PCS zave (nm): nm 40.0 (deionised
water).
Azide-functionalised nanoparticles 5
White solid (567 mg, 81%). PCS zave (nm): 37.6 (deionised water).
General procedure for the synthesis of doubly-functionalised
polyacrylamide nanoparticles: alkyne-amine bifunctionalized
nanoparticles 15
The synthesis of PANPs displaying two reactive functionalities
was performed according to the general procedure reported
above, adding commercially available 3-aminopropylacrylamide
to the aqueous solution of acrylamide monomers, according to
the following proportions: acrylamide (527 mg), N,N0-methyl-
enebisacrylamide (160 mg), 3-aminopropylacrylamide (7 mg),
acrylamide 4 (6 mg). The desired doubly-functionalised nano-
species were obtained as a white solid (609 mg, 87%). PCS zave
(nm) 39.8.
Azide-amine bifunctionalized nanoparticles 14
White solid (647 mg, 92%). PCS zave (nm) 43.8.
Alkyne-amine bifunctionalized nanoparticles embedding
aminodextran-conjugated CG-1 30
The synthesis of PANPs displaying two reactive functionalities
was performed according to the general procedure reported
above, replacing 40 mL of water in the aqueous solution with
40 mL of a 5 mg mL!1 aqueous solution of aminodextran-
conjugated calcium green 1. The desired particles were obtained
as a pale pink solid. (647 mg, 92%). PCS zave (nm) 37.7.
General procedure for the conjugation of amino-reactive
porphyrins and peptides to bifunctionalised nanoparticles:
nanoconjugates 21
Amino/alkyne-functionalised nanospecies 15 (100 mg) and were
dispersed in deionised water (20 mL). To the solution, porphyrin
16 (2 mg, 2.1 $ 10!3 mmol) was added, followed by TEA (20 mL,
1.4 $ 10!4 mmol). The resulting mixture was shielded from light
and shaken for 2 h on a rotating shaker. The desired conjugated
species were purified by gel filtration. Ethanol was added to the
eluate, and the particles were isolated by filtration through
membrane and dried in vacuo. (Green solid, 82 mg, 82%
recovery). PCS zave (nm) 99.8; UV/vis: (H2O) l (%): 442 (100),
567 (19.3), 613 (15.0).
Nanospecies 23
The conjugated nanospecies were obtained following the general
procedure, using nanospecies 15 (100 mg) and peptide 19 (4 mg,
6.3 $ 10!3 mmol). The desired nanoparticles were obtained as
a white solid. (70 mg, 70% recovery. PCS zave (nm) 89.5.
Nanoconjugates 25
The conjugated nanospecies were obtained following the general
procedure, using nanoparticles 14 (100 mg) and peptide 19 (4 mg,
6.3 $ 10!3 mmol). The desired nanoparticles were obtained as
a white solid. (74 mg, 74% recovery, PCS zave (nm) 103.1.
Nanoconjugates 27
The conjugated nanospecies were obtained following the general
procedure, using nanoparticles 15 (100 mg) and porphyrin 16
(2 mg, 2.1 $ 10!3 mmol). The desired nanoparticles were
obtained as a green solid. (79 mg, 79% recovery, PCS zave (nm)
110.1).
General procedure for the CuAAC reaction-based conjugation of
porphyrins to azide or alkyne-functionalised PANPs:
nanoconjugates 12
Nanoparticles 5 (60 mg) and were dispersed in deionised water (9
mL). To the solution, porphyrin 7 (2 mg, 2.1 $ 10!3 mmol) was
added, followed by 10 mM aqueous CuSO4 (250 mL, 2.5 mmol)
and 100 mM aqueous sodium ascorbate (250 mL, 25 mmol). The
resulting mixture was shielded from light and shaken overnight
on a rotating shaker. The desired conjugated species were































































purified by gel filtration. Ethanol was added to the eluate, and
the particles were isolated by filtration through membrane and
dried in vacuo. Green solid, 57 mg, 95% recovery, PCS zave (nm)
102.3; UV/vis: (H2O) l (%): 442 (100), 566 (20.3), 611 (15.7).
Nanoconjugates 13
Green solid, 50 mg, 83% recovery. PCS zave (nm) 92.3; UV/vis:
(H2O) l (%): 443 (100), 567 (17.1), 613 (13.0).
Nanoconjugates 22
Nanoconjugates 21 (60 mg) and were dispersed in deionised
water (9 mL). To the solution, peptide 18 (4 mg, 6.3 $ 10!3
mmol) was added, followed by 10 mM aqueous CuSO4 (250 mL,
2.5 mmol) and 100 mM aqueous sodium ascorbate (250 mL, 25
mmol). The resulting mixture was shielded from light and shaken
overnight on a rotating shaker. The desired conjugated species
were purified by gel filtration. Ethanol was added to the eluate,
and the particles were isolated by filtration through membrane
and dried in vacuo. (Green solid, 55 mg, 92% recovery). PCS zave
(nm) 96.9; UV/vis: (H2O) l (%): 442 (100), 566 (18.6), 618 (16.4).
Nanoconjugates 24
The conjugated nanospecies were obtained following the general
procedure, using nanoconjugates 23 (70 mg) and porphyrin 8
(4 mg, 4.1 $ 10!3 mmol). The desired nanoconjugates were
obtained as a green solid (63 mg, 90% recovery). PCS zave (nm)
70.0; UV/vis: (H2O) l (%): 442 (100), 567 (13.5), 612 (10.9).
Nanoconjugates 26
The conjugated nanospecies were obtained following the general
procedure, using nanospecies 25 (80 mg) and porphyrin 7 (4 mg,
4.1 $ 10!3 mmol). The desired nanoparticles were obtained as
a green solid (67 mg, 97% recovery). PCS zave (nm) 92.7; UV/vis:
(H2O) l (%): 442 (100), 566 (17.8), 613 (11.4).
Nanoconjugates 28
The conjugated nanospecies were obtained following the general
procedure, using nanospecies 21 (60 mg) and 1-a-propargyloxy-
mannose 20 (4 mg, 1.8 $ 10!2 mmol). The desired nanoparticles
were obtained as a green solid (54 mg, 90% recovery). PCS zave
(nm) 98.4; UV/vis: (H2O) l (%): 443 (100), 567 (16.3), 613 (16.4).
Nanoconjugates 29
The conjugated nanospecies were obtained following the general
procedure, using nanospecies 23 (60 mg) and 17 (3 mg, 2.7$ 10!2
mmol). The solvent for this reaction was 10% aqueous DMSO.
The desired nanoparticles were obtained as a blue solid (54 mg,
91% recovery). PCS zave (nm) 69.2; UV/vis: (H2O) l (%): 651
(94.6), 701 (100).
Synthesis of nanoconjugates 31
Nanospecies 30 (100 mg) and were dispersed in deionised water
(15 mL). To the solution, porphyrin 16 (1 mg, 1.0 $ 10!3 mmol)
was added, followed by TEA (50 mL, 3.6 $ 10!4 mmol). The
resulting mixture was shielded from light and shaken for 2 h on
a rotating shaker. The solution was filtered through Sephadex,
and to the green eluate containing the porphyrin-coated nano-
particles, an aqueous solution of peptide 18 (10 mgmL!1, 500 mL,
7.9 $ 10!3 mmol) was added, followed by 10 mM aqueous
CuSO4 (250 mL, 2.5 mmol) and 100 mM aqueous sodium
ascorbate (250 mL, 25 mmol). The resulting mixture was shielded
from light and it was shaken overnight on a rotating shaker. The
desired conjugated species were isolated by gel filtration and
precipitation with ethanol. Filtration through membrane and
drying in vacuo yielded the desired nanoparticles. (Green solid,
88 mg, 88% recovery). PCS zave (nm) 71.7; UV/vis: (H2O) l (%):
439 (100), 567 (18.3), 618 (22.5).
Sakaguchi test
The assay is based on the method described by Michael et al.,79
with minor modifications. Solutions: Reagent A: 5% urea and
0.05% 1-naphthol in 95% ethanol. Reagent B: 0.7% bromine in
1.25MNaOH. 5 mg mL!1 solutions of RGD-coated nanospecies
in deionised water were used as the samples. Positive control
samples were prepared using 1 mM Arg in deionised water.
Deionised water and 5 mg mL!1 suspension of nanospecies 15 in
deionised water were used as negative controls. Method: 250 mL
of sample solution were added to 250 mL of reagent A, followed
by 500 mL of reagent B in an eppendorf tube. The mixture was
mixed on a vortex shaker and then it was allowed to stand at
room temperature for 5 min. The solution was then transferred in
a quartz cuvette (1 mL) and the absorption spectrum was
recorded between 250 and 750 nm. The test was considered
positive when Isample/IQ!1 > 2 at 480 nm.
Phenol-sulfuric acid test
The assay was based on the micro-method described by Masuko
et al.77 Solutions: Reagent A: 5% phenol in deionised water.
Reagent B: concentrated H2SO4 (1.14 g mL
!1). 5 mg mL!1
solutions of nanospecies 27 in deionised water was used as ana-
lyte solution. Positive control samples were prepared using
10 mMmannose in deionised water. Deionised water (control C)
and 5 mg mL!1 suspension of nanospecies 15 in deionised water
(control D) were used as negative controls. Method: 450 mL of
reagent B were added to 150 mL of the analyte solution, followed
by 90 mL of reagent A in a test tube equipped with a stopper. The
mixture was mixed on a vortex shaker and then it was transferred
into a graphite bath and allowed to stand at 90 #C for 10 min.
The solution was then transferred in a quartz cuvette (1 mL) and
the absorbance of the sample was recorded between 400 and 550.
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